Locoregional therapies for early-stage prostate cancer

Oncology (Williston Park). 1995 Sep;9(9):803-11; discussion 815-6.


Widespread use of prostate-specific antigen (PSA) as a screening tool has led to an increased incidence of biopsy-proven prostate cancer, as well as a shift toward more cases with clinically confined disease (stage T1 to T2). The two traditional therapeutic modalities, radical prostatectomy and external-beam radiation therapy, have undergone technical refinements. Other modalities, such as brachytherapy and cryosurgery, are also being used to treat early-stage disease. Comparisons between treatment results are difficult. Biochemical failure, based on PSA findings, is currently used to measure treatment efficacy, but the precise definition and clinical relevance of biochemical failure have yet to be established. The author presents current analyses of biochemical failure, cause-specific survival, distant metastasis, and morbidity rates following various treatment modalities.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Male
  • Prognosis
  • Prostate-Specific Antigen / analysis
  • Prostatectomy
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / therapy*
  • Radiotherapy
  • Survival Rate


  • Prostate-Specific Antigen